文献速递心脑血管急症消化、代谢与肾脏急症

英国常规收集数据与临床试验裁决直接随访数据在严重血管事件记录中的准确性与完整性比较:ASCEND随机临床试验的二次分析

Comparison of the Accuracy and Completeness of Records of Serious Vascular Events in Routinely Collected Data vs Clinical Trial-Adjudicated Direct Follow-up Data in the UK: Secondary Analysis of the ASCEND Randomized Clinical Trial.
PubMed 文献 · JAMA Netw Open · 2021-12-01
一句话结论ASCEND试验事后分析提示,英国常规住院与死亡登记数据可作为心肌梗死、缺血性卒中住院、血管性死亡和动脉血运重建的唯一随访方法,无需临床裁决验证。

该研究为ASCEND随机临床试验的二次分析,纳入15480例无动脉粥样硬化性血管疾病证据的糖尿病患者,随机接受阿司匹林100mg每日一次或安慰剂、ω-3脂肪酸1g每日一次或安慰剂,平均随访7.4年。比较裁决直接随访与常规收集数据对严重血管事件(SVE)的识别准确性:SVE一致性强度高(1401 vs 1127事件;κ=0.78;敏感性72.0%;特异性99.2%),排除TIA后敏感性提高至80.6%。阿司匹林比较的率比在裁决随访与常规数据随访下分别为0.88 vs 0.91(主要终点)、0.92 vs 0.91(排除TIA的SVE),ω-3脂肪酸比较结果类似,裁决似乎未明显改变率比。作者认为英国常规住院与死亡登记数据可作为主要预防心血管试验中上述结局的唯一随访方法。

要点

  • 在15480例糖尿病患者中,常规数据与裁决随访对SVE的一致性强度高(1401 vs 1127事件;κ=0.78,95%CI 0.76-0.80)。
  • 常规数据识别SVE的敏感性为72.0%(95%CI 69.7%-74.4%),特异性为99.2%(95%CI 99.0%-99.3%)。
  • 排除TIA后敏感性提高至80.6%(95%CI 78.3%-82.9%)(1129 vs 1026事件)。
  • 阿司匹林比较的率比:裁决随访0.88(95%CI 0.79-0.97)vs 常规数据0.91(95%CI 0.81-1.02)(主要终点)。
  • 作者认为常规住院与死亡登记数据可作为心肌梗死、缺血性卒中住院、血管性死亡和动脉血运重建的唯一随访方法,无需临床裁决验证。

适用人群与场景

  • ASCEND试验人群:英国糖尿病患者,无动脉粥样硬化性血管疾病证据,年龄均值63岁(SD 9),男性9684例(62.6%)。
  • 场景:初级预防心血管试验的随访数据源比较,非急诊或ICU床旁直接应用。

研究设计与关键结果

  • 研究类型:随机临床试验(ASCEND)的二次分析;样本量15480例;英国;2005年6月24日至2011年7月28日随机化,随访至2017年7月31日完成,事后分析于2018年9月1日至2021年10月1日进行。
  • 干预:2×2析因设计,阿司匹林100mg每日一次 vs 匹配安慰剂,以及ω-3脂肪酸1g每日一次 vs 安慰剂。
  • 主要终点:SVE复合终点(非致死性心肌梗死、缺血性卒中、短暂性脑缺血发作[TIA]或血管性死亡,排除出血性卒中)。
  • SVE一致性:裁决直接随访1401事件 vs 常规数据1127事件;κ=0.78(95%CI 0.76-0.80);敏感性72.0%(95%CI 69.7%-74.4%);特异性99.2%(95%CI 99.0%-99.3%)。
  • 排除TIA的SVE:1129 vs 1026事件;敏感性80.6%(95%CI 78.3%-82.9%)。
  • 阿司匹林比较率比:主要终点裁决随访0.88(95%CI 0.79-0.97)vs 常规数据0.91(95%CI 0.81-1.02);排除TIA的SVE裁决随访0.92(95%CI 0.82-1.03)vs 常规数据0.91(95%CI 0.80-1.02)。
  • ω-3脂肪酸比较结果类似,裁决似乎未明显改变率比。

证据类型、等级与局限

  • 证据类型:随机临床试验的二次分析(事后分析)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,英国常规收集的住院和死亡登记数据可作为心肌梗死、缺血性卒中住院、血管性死亡和动脉血运重建的唯一随访方法,用于初级预防心血管试验,无需临床裁决验证。
  • 该结论基于ASCEND试验的事后分析,不涉及急诊或ICU床旁患者管理决策。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Routinely collected data could substantially decrease the cost of conducting trials.

OBJECTIVE: To assess the accuracy and completeness of UK routine data for ascertaining serious vascular events (SVEs) compared with adjudicated follow-up data.

DESIGN, SETTING, AND PARTICIPANTS: This was a secondary analysis of a randomized clinical trial. From June 24, 2005, to July 28, 2011, the ASCEND (A Study of Cardiovascular Events in Diabetes) primary prevention trial used mail-based methods to randomize people with diabetes without evidence of atherosclerotic vascular disease using a 2 × 2 factorial design to aspirin and/or ω-fatty acids vs matching placebo in the UK. Direct participant mail-based follow-up was the main source of outcome data, with more than 90% of the primary outcome events undergoing adjudication. Follow-up was completed on July 31, 2017. In parallel, more than 99% of participants were linked to routinely collected hospital admission and death registry data (ie, routine data), enabling post hoc randomized comparisons of different sources of outcome data (conducted from September 1, 2018, to October 1, 2021).

INTERVENTIONS: Random allocation to 100 mg of aspirin once daily vs matching placebo and separately to 1 g of ω-3 fatty acids once daily vs placebo.

MAIN OUTCOMES AND MEASURES: The primary outcome consisted of SVEs (a composite of nonfatal myocardial infarction, ischemic stroke, transient ischemic attack [TIA], or vascular death, excluding hemorrhagic stroke).

RESULTS: A total of 15 480 participants were randomized (mean [SD] age, 63 [9] years; 9684 [62.6%] men) and followed up for a mean (SD) of 7.4 (1.8) years. For SVEs, agreement between adjudicated direct follow-up and routine data sources was strong (1401 vs 1127 events; κ = 0.78 [95% CI, 0.76-0.80]; sensitivity, 72.0% [95% CI, 69.7%-74.4%]; specificity, 99.2% [95% CI, 99.0%-99.3%]), and sensitivity improved for SVEs excluding transient ischemic attack (1129 vs 1026 events; sensitivity, 80.6% [95% CI, 78.3%-82.9%]). Rate ratios for the aspirin-randomized comparison for adjudicated direct follow-up vs follow-up solely through routine data alone were 0.88 (95% CI, 0.79-0.97) vs 0.91 (95% CI, 0.81-1.02) for the primary outcome and 0.92 (95% CI, 0.82-1.03) vs 0.91 (95% CI, 0.80-1.02) for SVEs excluding TIA. Results were similar for the ω-3 fatty acid comparison, and adjudication did not seem to markedly change rate ratios.

CONCLUSIONS AND RELEVANCE: Post hoc analyses of the ASCEND trial suggest that routinely collected hospital admission and death registry data in the UK could be used as the sole method of follow-up for myocardial infarction, ischemic stroke resulting in hospitalization, vascular death, and arterial revascularization in primary prevention cardiovascular trials, without the need for verification by clinical adjudication.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Harper C, Mafham M, Herrington W, et al. Comparison of the Accuracy and Completeness of Records of Serious Vascular Events in Routinely Collected Data vs Clinical Trial-Adjudicated Direct Follow-up Data in the UK: Secondary Analysis of the ASCEND Randomized Clinical Trial. JAMA Netw Open. 2021. PMID: 34962561. doi:10.1001/jamanetworkopen.2021.39748

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。